You just read:

New Real World Evidence (RWE) Study Confirms Cost Effectiveness of Iressa® (gefitinib) Under Single Payment Access (SPA) Scheme in UK

News provided by

AstraZeneca UK

08 Nov, 2012, 11:40 GMT